SDGR

Schrodinger Inc

Add to Watchlist

Advanced Chart

22.490

-0.54(-2.345%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

22.9809

Open

22.880

VWAP

22.61

Vol

833.66K

Mkt Cap

1.65B

Low

22.345

Amount

18.85M

EV/EBITDA(TTM)

Total Shares

72.68M

1.19B

EV/OCF(TTM)

45.80

P/S(TTM)

7.28

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

52.03M

+9.93%

50.09M

+41.95%

91.98M

+4.14%

Estimates Revision

The market is revising Upward the revenue expectations for Schrödinger, Inc. (SDGR) for FY2025, with the revenue forecasts being adjusted by 0.26% over the past three months. During the same period, the stock price has changed by -14.97%.

Revenue Estimates for FY2025

Revise Upward

+0.26%

In Past 3 Month

Stock Price

Go Down

-14.97%

In Past 3 Month

9 Analyst Rating

41.00% Upside

Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is 31.71 USD with a low forecast of 26.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

41.00% Upside

Current: 22.490

Low

26.00

Averages

31.71

High

39.00

41.00% Upside

Current: 22.490

Low

26.00

Averages

31.71

High

39.00

Morgan Stanley

Sean Laaman

Equal Weight

downgrade

$31 -> $28

2025-07-03

Reason

Morgan Stanley

Sean Laaman

Price Target

$31 -> $28

2025-07-03

downgrade

Equal Weight

Reason

Morgan Stanley analyst Sean Laaman assumed coverage of Schrodinger with an Equal Weight rating with a price target of $28, down from $31. Schrodinger has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. Schrodinger's software business provides a steady stream of revenue that acts as a safety net for the stock, regardless of the outcomes of partnerships and the proprietary pipeline, the firm says.

Keybanc

Scott Schoenhaus

Buy

Maintains

$30 → $32

2025-04-16

Reason

Keybanc

Scott Schoenhaus

Price Target

$30 → $32

2025-04-16

Maintains

Buy

Reason

KeyBanc analyst Scott Schoenhaus raised the firm's price target on Schrodinger to $32 from $30 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.

Piper Sandler

Joseph Catanzaro

Buy

Maintains

$50 → $45

2025-02-27

Reason

Piper Sandler

Joseph Catanzaro

Price Target

$50 → $45

2025-02-27

Maintains

Buy

Reason

Piper Sandler lowered the firm's price target on Schrodinger to $45 from $50 and keeps an Overweight rating on the shares following quarterly results. The firm notes Schrodinger reiterated that it expects to report initial clinical data from 3 programs in 2025. Specifically, it refined guidance for SGR-1505, now expecting to report data in Q2 2025.

Keybanc

Scott Schoenhaus

Buy

Maintains

$25 → $27

2025-01-24

Reason

Keybanc

Scott Schoenhaus

Price Target

$25 → $27

2025-01-24

Maintains

Buy

Reason

KeyBanc raised the firm's price target on Schrodinger to $27 from $25 and keeps an Overweight rating on the shares. The firm thinks a more premium valuation multiple is deserved given the company's recurring, high-margin revenue streams; combined with large internal pipeline opportunities.

BMO Capital

Gary Nachman

Buy

Maintains

$25 → $28

2024-11-13

Reason

BMO Capital

Gary Nachman

Price Target

$25 → $28

2024-11-13

Maintains

Buy

Reason

BMO Capital

Gary Nachman

Buy

Maintains

$30 → $25

2024-10-17

Reason

BMO Capital

Gary Nachman

Price Target

$30 → $25

2024-10-17

Maintains

Buy

Reason

BMO Capital analyst Evan Seigerman lowered the firm's price target on Schrodinger to $25 from $30 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results in BioPharma. The company's shift towards internally-developed assets is reflected in its softer FY24 drug discovery revenue guide, but while this guidance no longer includes estimates for unrealized milestone payments, it is leaving room for upside in the back half of the year, the analyst tells investors in a research note. BMO adds that it remains positive on the potential of Schrodinger's pipeline, with clinical execution driving share upside in 2024 and beyond.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Schrodinger Inc (SDGR.O) is -9.49, compared to its 5-year average forward P/E of -0.57. For a more detailed relative valuation and DCF analysis to assess Schrodinger Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.57

Current PE

-9.49

Overvalued PE

244.45

Undervalued PE

-245.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-22.56

Current EV/EBITDA

-7.81

Overvalued EV/EBITDA

4.76

Undervalued EV/EBITDA

-49.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

15.33

Current PS

6.16

Overvalued PS

27.08

Undervalued PS

3.59

Financials

Annual

Quarterly

FY2025Q1

YoY :

+62.72%

59.55M

Total Revenue

FY2025Q1

YoY :

-24.53%

-50.89M

Operating Profit

FY2025Q1

YoY :

+9.29%

-59.81M

Net Income after Tax

FY2025Q1

YoY :

+7.89%

-0.82

EPS - Diluted

FY2025Q1

YoY :

-430.79%

143.47M

Free Cash Flow

FY2025Q1

YoY :

+1.26%

52.26

Gross Profit Margin - %

FY2025Q1

YoY :

-111.40%

9.61

FCF Margin - %

FY2025Q1

YoY :

-32.84%

-100.43

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 214.18% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

650.2K

USD

6-9

Months

0.0

USD

0-12

Months

27.2K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

200.0K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.1M

Volume

Months

6-9

1.3M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 214.18% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

650.2K

USD

6-9

Months

0.0

USD

0-12

Months

27.2K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SDGR News & Events

Events Timeline

2025-06-12 (ET)

2025-06-12

07:59:15

Schrodinger announces initial clinical data from SGR-1505 study

2025-05-29 (ET)

2025-05-29

08:04:18

Schrodinger appoints Mannix Aklian as chief commercial officer

2025-05-20 (ET)

2025-05-20

06:32:05

Schrodinger says Richie Jain to succeed Geoffrey Porges as CFO

News

7.0

07-06Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

7.0

07-02PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

7.0

06-28Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

People Also Watch

Liberty Broadband Corp

Helix Energy Solutions Group Inc

Dime Community Bancshares Inc

FAQ

What is Schrodinger Inc (SDGR) stock price today?

The current price of SDGR is 22.49 USD — it has decreased -2.34 % in the last trading day.

SDGR

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

SDGR News & Events

Events Timeline

News

People Also Watch

FAQ

What is Schrodinger Inc (SDGR) stock price today?

What is Schrodinger Inc (SDGR)'s business?

What is the price predicton of SDGR Stock?

What is Schrodinger Inc (SDGR)'s revenue for the last quarter?

What is Schrodinger Inc (SDGR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Schrodinger Inc (SDGR)'s fundamentals?

How many employees does Schrodinger Inc (SDGR). have?

What is Schrodinger Inc (SDGR) market cap?